Multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of upadacitinib in subjects with giant cell arthritis. SELECT-GCA
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: ABBVIE SPAIN SLU
- Phase: III
- Execution start: 18/01/2021
- End of execution: 30/11/2024
- IP: RAFAEL CALIZ CALIZ